

Premium Editing Sample

Case Report

Symptoms of Acute Appendicitis Masquerading Overlapping with Distal Intestinal Obstruction Syndrome in Adult Cystic Fibrosis

Sushant M. Nanavati ¹, Hiren Patel ², Gabriel Melki,¹ Vinod Kumar,¹ Edward Milman,³

Patrick Michael,¹ and Ariy Volfson²

¹ Department of Internal Medicine, St. Joseph's University Medical Center-New

York Medical College, USA ²Department of Gastroenterology, St. Joseph's

University Medical Center-New York Medical College, USA ³Department of

Radiology, St. Joseph's University Medical Center-New York Medical College,

USA

Correspondence should be addressed to Sushant M. Nanavati;

snav2@gmail.com

Commented [A1]: Thanks for providing this opportunity to assist you with this manuscript. I have edited the text for language, grammar, and improved clarity. I have also checked the manuscript for conformance with the formatting guidelines provided. In the cases where additional information is required from you, I have added comments to bring them to your attention. Should you have any concerns, please feel free to get back to me. My best wishes for your success with the manuscript.

Commented [A2]: Please note that *Case Reports in Gastrointestinal Medicine* encourages authors to use the CARE checklist to improve the reporting of their case report. Therefore, please consider following this checklist. I have included comments where information could be included as per these guidelines.

Commented [A3]: I have revised this according to the reviewer's comment. However, I have also included "symptoms of" at the beginning to make the title clearer.

Commented [A4]: According to journal guidelines, please ensure that you include details of the full institutional mailing addresses and email addresses.

Abstract

~~Overshadowed by Sino-pulmonary infections, With the improved life expectancy in c~~Cystic F~~F~~ibrosis (CF) patients, there has been an increase in ~~commonly affects~~ gastrointestinal ~~organs-manifestations~~ because of secretory and motility dysfunction. Infrequently, these changes ~~can~~ result in ~~d~~Distal ~~i~~ntestinal ~~O~~bststruction ~~s~~ndrome (DIOS), an ~~more and more increasingly~~ diagnosed gastrointestinal ~~conditionentity~~ in adult ~~Cystic-FibrosisCF~~ patients. We present ~~thea~~ case ~~of a~~ 22-year-old ~~manle~~ who presented to our hospital with right lower quadrant abdominal pain, ~~with-Despite the~~ suspicion of acute appendicitis, ~~the patient and~~ was subsequently diagnosed ~~as-with~~ DIOS. ~~Our case highlights the importance of considering~~ DIOS as ~~a~~ differential diagnosis ~~of-for~~ right lower quadrant abdominal pain in CF patients, especially ~~for~~ ~~by~~ physicians working at community hospitals ~~thatwhich~~ may not have a ~~C~~F~~F~~ibrosis care program available.

Commented [A5]: The abstract is within the 200-word limit.

Commented [A6]: I have deleted this, as sino-pulmonary infections have not been mentioned elsewhere in the main text. If you do wish to include this, then please consider elaborating on this a little further in the in the introduction/ discussion. I have, instead, added information that has been used in the introduction to serve as background here. Please review this change.

Commented [A7]: While the significance of the case is mentioned here, its novelty is not. How is this case report contributing to the literature? Have no similar cases been reported previously? The journal reviewer has also commented on the fact that the novelty is unclear. Thus, I suggest you highlight this in the abstract and main text.

1. Introduction

Cystic F~~F~~ibrosis (CF) is a genetic disease ~~of-that affects~~ multiple organs. ~~With-Because of~~ ~~advancementsing in the~~ ~~managemening of~~ CF ~~patients,~~ patients ~~can~~ now ~~often-survive become-to~~ adulthood [1]. ~~However, the i~~Improved life expectancy among adult CF patients has ~~given-riseled~~ to ~~an increase in~~ extrapulmonary, notably gastrointestinal, man-ifestations, which ~~did-not-happen-was~~ previously ~~uncommon~~. Distal ~~i~~ntestinal ~~o~~bststruction ~~S~~ndrome (DIOS) continues to be a rising complication in adult CF patients, presenting ~~aswith~~ acute abdominal pain ~~like-and mimicking~~ an acute abdominal emergency.

Commented [A8]: The format of the in-text citations follows the journal guidelines, which states that references must be numbered consecutively and citations of references in text should be identified using numbers in square brackets.

Commented [A9]: Please include the relevant citation here.

~~We report the case of a 22-year-old man with a history of CF who presented to our hospital with right lower quadrant~~ abdominal pain. ~~Despite the initial suspicion of acute appendicitis, he was subsequently diagnosed with DIOS.~~

Formatted: Indent: Left: 0.42 cm

2. Case Report Presentation

A 22-year-old Turkish-origin ~~manle~~ with a past medical history of ~~Cystic-FibrosisCF~~ presented with a one-day

Commented [A10]: As per CARE guidelines, please consider including medical, family, and psychosocial history including genetic information if possible.

Formatted: Font: Bold

Formatted: Font: Bold

history of right lower quadrant abdominal pain. He described a sharp periumbilical pain that continued to worsen, which then shifted to the right lower quadrant of the abdomen. Prior to the onset of the abdominal pain, he reported experiencing nausea and anorexia for three days. His last bowel movement was two days prior to admission. The patient was also diagnosed with CF Cystic Fibrosis at the age of four, and the his disease progressed to exocrine pancreatic insufficiency, which was being treated with pancreatic enzymes. Upon reviewing the patient's past history, it was noted that he had several episodes of pneumonia, for which he was appropriately treated with antibiotics. Notably, no history of constipation or recurrent abdominal discomfort was reported prior to this. At home, the patient was prescribed Albuterol inhalation as needed, Dornase Alfa inhalation, Aztreonam lysine nebulization, 500 mg Azithromycin three times a week, Lansoprazole, Lumacaftor-ivacaftor twice a day, Lipase-pancreas-enzyme capsule three times a day, and a multivitamin capsule once a day. The patient was also diagnosed with Cystic Fibrosis at the age of four and his disease progressed to exocrine pancreas insufficiency, which was being treated with pancreatic enzymes. On abdominal examination, he was found to have had diminished bowel sounds and tenderness on right lower quadrant with equivocal rebound tenderness on the right lower quadrant. Laboratory analysis showed leukocytosis (white blood cell count, WBC 13.0 mm/K3; Neutrophils count, 62%) with a normal differential. He had no electrolyte imbalances. Computed Tomography (CT) of the Abdomen revealed thickening, and edema around the terminal ileum, inflammatory changes in the a colon with inflammatory changes, free fluid in the right paracolic gutter adjacent to the cecum, an appendix measuring 5.3x4.6 mm, and reactive lymph nodes (Figures 1 and 2).

Commented [A11]: I have moved these statements from later in the paragraph to improve flow within the paragraph. I believe the statement would be better suited here where the patient's history is being described.

Commented [A12]: Please consider specifying the dosage and form of intake for all drugs to ensure consistency.

Commented [A13]: I have deleted this abbreviation as it has not been subsequently used in the main text. Figure legends generally require abbreviations to be spelled out separately.

Medicine




FIGURE 1: Axial abdominal computed tomography scan depicting thickening around the terminal ileum and colon (yellow arrows) along with extraluminal fluid and reactive lymph nodes.




FIGURE 2: Coronal view computed tomography scan with showing thickening of the ileum with a distended appendix (yellow arrows).

measuring 5.8–4.6 mm, and reactive lymph nodes (Figures 1 and 2). Due to extraluminal fluid and cecal wall edema with inflammation, early acute appendicitis could not be excluded as a possible diagnosis. Surgical intervention was performed required, which revealed a ruptured microperforation of a cecal diverticulum and a distended appendix in chronic adhesions, for which he required an appendectomy and partial cecectomy with an intact ileocecal valve (IC-valve) valve. Postoperatively, he was diagnosed with DIOS and was subsequently started on pPolyethylene gGly-col. The patient made an unremarkable recovery and was discharged. home to be He was

Formatted: Indent: Left: 0.2 cm, Space Before: 3.1 pt, Tab stops: 11.83 cm, Left

Commented [A14]: Upon submission of an article, authors are supposed to include all figures and tables in the PDF file of the manuscript. If the article is accepted, authors will be asked to provide the source files of the figures.

Commented [A15]: The use of “in” is a little unclear. Do you mean to say distended appendix with/caused by chronic adhesions instead?

Commented [A16]: Please consider elaborating on how/why this diagnosis was made postoperatively, or how DIOS was distinguished from appendicitis, as this is unclear here.

Commented [A17]: Please consider providing more information on the dosage and duration of this treatment.

followed up in the outpatient clinic ~~without and did not have any~~ recurrence of any symptoms.

Commented [A18]: As per CARE guidelines, consider including follow-up diagnostic and intervention adherence if possible.

3. Discussion

Commented [A19]: Please note, while the discussion section discusses the known facts about the condition, there has been no mention of the present case and how the case relates to the existing literature on the topic. I have therefore included this here to put the case in context to the literature. Please review this addition. Ideally, this discussion of the characteristics of the condition should be included in the Introduction section and this section should discuss this case in the context of previously reported cases.

4. ~~Due to the improved life expectancy of CF patients, DIOS is now being increasingly diagnosed in adult patients with CF.~~ Distal Intestinal Obstruction Syndrome (DIOS) was called a Meconium Ileus equivalent in the past, described by the collection of viscid fecal material within the lumen combined with sticky mucoid intestinal content adherent to the intestinal wall of the terminal ileum and cecum [1]. Perez-Aguilar et al. reported ~~a that the~~ prevalence of DIOS was 19.5% (mean age 20.6 years) among 46 CF patients in a retrospective analysis, while Dray et al. ~~conducted a cross-sectional study~~ reporting a 15.8% (mean age 28.9 years) prevalence ~~in among~~ 171 CF patients in a cross-sectional study [2, 3]. ~~Despite the~~ ~~Though there continues to be a~~ limited assessment ~~of on~~ the prevalence of DIOS in adult CF patients, DIOS is considered more common among adults ~~compared to~~ than among children ~~due to~~ because of increased disease progression.

Commented [A20]: I have added this sentence from the introduction to add some context about DIOS before discussing its prevalence. Please review this change and ensure that you include the relevant citation here.

5. ~~Distal Intestinal Obstruction Syndrome (DIOS), previously known as was called a Meconium Ileus equivalent, in the past, described~~ is characterized by the collection of viscid fecal material within the lumen combined with sticky mucoid intestinal content adherent to the intestinal wall of the terminal ileum and cecum [1]. Defective intestinal chloride and water secretions into the gut, luminal acidity, and loss of bile salt all contribute to the development of DIOS [1]. These patients characteristically present with right lower quadrant pain, nausea, abdominal distension, and failure to pass stools or flatus [1, 3]. In some patients, a palpable right lower quadrant mass ~~can may be~~ appreciated present that may be confirmed on abdominal ~~radiography~~ X-ray [1]. Though abdominal ~~X-rays are~~ radiography is recommended to aid in the diagnosis of DIOS, ~~they are it is~~ inadequate in differentiating ileus from other causes of abdominal pathologies that may present in Cystic Fibrosis CF patients [4]. Due to ~~the proximity of~~ the anatomical ~~locations~~ proximity, as well as the overlapping clinical presentations, appendicitis and intussusception may mimic DIOS. ~~This which~~ further leads to diagnostic uncertainty. ~~Overlap of several intra-abdominal pathologies in CF increases the risk of misdiagnosis, especially with acute appendicitis,~~ as these patient's underlying pathologies may be masked in CF patients with pulmonary infections using antibiotics, as seen in our case [5, 6].

Formatted: Indent: Left: 0.42 cm, No bullets or numbering

Commented [A21]: I believe this sentence would be more appropriate here as this paragraph describes the characteristics and diagnosis of DIOS.

Commented [A22]: I have deleted this sentence as it was a repetition of the previous sentence (i.e. overlapping pathologies between appendicitis and DIOS leading to misdiagnosis). Please review these changes to ensure you agree with them.

Osmotic laxatives are the cornerstone of bowel regimens for the treatment of DIOS. The most commonly prescribed laxative is polyethylene glycol (PEG) administered at a dose of 20–40 ml/kg/h, up to a maximum of 1 L/kg/h for a total of 8 hours, resulting in achieving fecal effluent consisting of clear fluid, along with the resolution of abdominal pain and constipation [1, 6]. If the diagnosis remains unclear, and thus, requires surgical intervention, ileocecal valve resection should be considered to prevent the development and recurrence of intestinal obstruction sequelae and growth, especially in adolescents [7].

With the increase in immigration of foreigners into America, inner-city and community hospitals may not be sufficiently equipped with a Cystic Fibrosis CF care center; moreover, these hospitals may not have programs in provision, with expertise available to other clinicians involved in patient care. Therefore, our case highlights the significance of considering DIOS as a differential diagnosis in patients with a history of CF presenting with right lower quadrant abdominal pain and constipation, particularly in hospitals without a CF care program available.

Consent

Informed consent was obtained from the patient for this case report.

Conflicts of Interest

Authors' Contributions

All authors contributed to the revision and approval of the manuscript.

Acknowledgements

References

1. C. Colombo, H. Ellemunter, R. Houwen, A. Munck, C. Taylor, and M. Wilschanski, "Guidelines for the

Commented [A23]: Please discuss the corresponding outcomes noted in the patient described in this case report.

Commented [A24]: As per CARE guidelines, consider discussing the strengths and limitations in your approach to this case

Commented [A25]: The relationship between the two parts of this sentence was not clearly established, as it was unclear how immigration affected care centers' ability to manage patients. I have added this term to make this association clearer.

Commented [A26]: Please note that Case reports submitted to Hindawi should conform to the International Committee of Medical Journal Editors' (ICMJE) recommendations. Hindawi reserves the right to request copies of consent documentation at any time

Commented [A27]: As per the reviewer's comment, please specify if the patient consented to the publication of this case e.g. "Informed consent was obtained from the patient for the publication of this case report."

Commented [A28]: Please include acknowledgements (if any) such as supporting grants, presentations, and so forth.

Commented [A29]: There are no specific instructions on the reference formatting for this journal. I have therefore ensured consistency and accuracy for the references, maintaining the predominant style used. I have also ensured correspondence between the in-text citations and references.

diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients,” *Journal of Cystic Fibrosis*, vol. 10, pp. S24–S28, 2011.

2. F. Perez-Aguilar-F, J. Ferrer-Calvete-J, D. Nicolas-D, Berenguer-J, and J. Ponce-J. “Digestive alterations in cystic fibrosis. Retrospective study of a series of 46 adult patients.” *Gastroenterología y Hepatología* *Gastroenterología y hepatología*, 1999 Feb; vol. 22, no. (2); pp. 72–78, 1999.

~~2.~~

~~3.~~ X. Dray, T. Bienvenu, N. Desmazes-Dufeu, et al, "Distal intestinal obstruction syndrome in adults with cystic fibrosis," [Clinical Gastroenterology and Hepatology](#) ~~Clin Gastroenterol Hepatol~~, vol. 2, no. 6, pp. 498–503, 2004.

~~3.~~

~~4.~~ K. Nassenstein, B. Schwerger, M. Kammer, J. Status, T. Lauenstein, and J. Barkhausen, "Distal intestinal obstruction syndrome in the early postoperative period after lung transplantation in a patient with cystic fibrosis: morphological findings on computed tomography," *Gut*, vol. 54, no. 11, pp. 1662–1663, 2005.

~~4.~~

~~5.~~ Y. Al Abed, Y. W. Hameed, J. W., Roy, J., and A.P.S. & Kumar, A. P. S. (2007). "Appendicitis in an adult patient with cystic fibrosis: a diagnostic challenge." *Gut*, vol. 56, no. (12), pp. 1799–1800, 2007.

~~5.~~

~~6.~~

~~7.~~ J. M. Abraham and C. J. Taylor, "Cystic Fibrosis & disorders of the large intestine: DIOS, constipation, and colorectal cancer," *Journal of Cystic Fibrosis*, supplement 2, pp. S40–S49, 2017.

7. A. Mentessidou, I. Loukou, G. Kampourglou, A. et al, "Long-term intestinal obstruction sequelae and growth in children with cystic fibrosis operated for meconium ileus: expectancies and surprises," [Journal of Pediatric Surgery](#), vol. 2018; 53, no. (8, pp.) 1504–1508 2018.

Title: Acute Appendicitis Masquerading Distal Intestinal Obstruction Syndrome in Adult Cystic Fibrosis

Thank you for submitting the above manuscript.

Below please find a list of comments and changes to be made to the manuscript. Please make all necessary revisions and email us the revised manuscript.

We encourage you to send your revision within 45 days.

When submitting your revision please include the following items:

- A rebuttal letter that responds to each point brought up by the academic editor and reviewer(s) as a 'Response to Reviewers' file.
- A clean revised manuscript as your 'Manuscript' file.
- A marked-up copy of the changes made from the previous article file as a 'Revised Manuscript with Track Changes' file. This can be done using 'track changes' in programs such as MS Word and/or highlighting any changes in the new document.

Thank you for your thoughtful suggestions and insights, which have enriched the manuscript and produced a better and more balanced account of the research.

The manuscript has been rechecked and appropriate changes have been made in accordance with the suggestions. The responses to the comments have been prepared and are given below. We hope that the revised manuscript is now suitable for publication in your journal.

Major points:

1. The title of the case is misleading. Since the patient had both appendicitis and DIOS, there was no 'masquerading'.

Response: Thank you for your comment. We have revised the title to "Symptoms of Acute Appendicitis Overlapping with Distal Intestinal Obstruction Syndrome in Adult Cystic Fibrosis"

2. The novelty of the case is not apparent from the Introduction. If DIOS is already associated with acute abdominal pain and abdominal emergency, what is the novelty here?

Response: Thank you for your comment. **Our case is novel** because we used the patient's cystic fibrosis (CF) history to diagnose distal intestinal obstruction syndrome (DIOS), despite the initial diagnosis of appendicitis. Therefore, we were able to successfully treat the patient accordingly. We would like to highlight that physicians should consider a diagnosis of DIOS for abdominal pain in CF patients.

3. There is no clear conclusion to the case. Please add a concluding sentence to the manuscript.

Response: Thank you for your suggestion. We have added the following sentence at the end of the Discussion of the revised manuscript.

"Therefore, our case highlights the importance of considering DIOS as a differential diagnosis in patients with a history of CF presenting with abdominal pain and constipation."

4. Was consent obtained from the patient for publishing this case?

Response: Thank you for your query. **We have included a section on patient consent in the manuscript.**

5. The Introduction doesn't flow well into the Case Report. End of the Introduction section should have introduction of case.

Response: Thank you for your suggestion. We have added the following sentence at the end of the

Commented [A30]: Thank you for sending in your responses to the reviewer comments for editing. I have edited the responses for language, checked that they adequately answer the reviewers' questions, and included comments where additional information is needed. I have also checked the manuscript to ensure that the required changes have been made to the manuscript. I have also prepared a response to the general comments for you to use during resubmission.

Commented [A31]: I have changed the title of the manuscript accordingly and included "symptoms of" at the beginning of the title for better clarity.

Commented [A32]: Is this the first case to report on this? If so then please consider stating this, as this would highlight its novelty.

Commented [A33]: I have included this in the revised manuscript.

Commented [A34]: Please specify whether the patient consented to the publication of this case report e.g. "Informed consent was obtained from the patient for the publication of this case report" in the manuscript. I have included a placeholder in the manuscript for where this information should be included.

Introduction of the revised manuscript: "We report the case of a 22-year-old man with a history of CF who presented to our hospital with right lower quadrant abdominal pain. Despite the initial suspicion of acute appendicitis, he was subsequently diagnosed with DIOS."

Commented [A35]: I have included this in the revised manuscript.

Minor points:

1. The yellow arrows in the figure are not visible. Please use thicker arrows to point to the relevant sections.

Response: Thank you for this suggestion. We have updated the figures.

Commented [A36]: Please consider specifying how the figures have been updated i.e. were the yellow arrows made more visible?

Life Sciences Sample

Case Report

Methylmalonic Acidemia with Novel MUT Gene Mutations

Inusha Panigrahi, Savita Bhunwal, Harish Varma, and Simranjeet Singh

Department of Pediatrics, Advanced Pediatric Centre, PGIMER, Chandigarh, India

Correspondence: Inusha Panigrahi; inupan@yahoo.com

Abstract

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency of the enzyme methylmalonyl-CoA mutase. The disease is characterized presented in early infancy by lethargy, vomiting, failure to thrive, and encephalopathy and is fatal deadly if left untreated. A 5-years-old boy presented with poor weight gain and recurrent episodes of fever, feeding problems, and lethargy, since from the age of 11 months, and poor weight gain. He was admitted to our hospital and evaluated for metabolic disorders; he was causes and diagnosed with as methylmalonic acidemia (MMA). He was treated with vitamin B12 and carnitine supplements and has been on followed-up for the last three3 years. Mutation analysis by next generation sequencing (NGS), and supplemented with Sanger sequencing, revealed two novel variants in exon 5 and 3 of the *MUT* gene responsible for the MMA in exon 5 and exon 3. Recently, he developed dystonic movements including orofacial dyskinesia. Our results indicate the necessity of genetic testing if MMA is suspected; it would can confirm the diagnosis, aid in selecting treatment options, and may enrich the panel of responsible gene variants.

1. Introduction

Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency of the enzyme methylmalonyl-CoA mutase. MMA presents with lethargy, acidosis, hypoglycemia/ hyperglycemia, ketosis, and recurrent episodes. MMA due to mutations in the MUT gene mutations, which encodes the enzyme methylmalonyl-CoA mutase, usually leads to severe phenotypes, and around 35–40% of the cases are due to novel new mutations [1, 2]. There can be M missense or nonsense mutations, deletions, insertions, and so on in the MUT gene can and so on leading to a clinical phenotype, and these-

Variants of the MUT gene encoding the enzyme methylmalonyl CoA mutase are responsible for about 60% of MMA cases; mut0 and mut- phenotypes are caused by complete and partial enzyme deficiency, respectively. Variations in the MMAA, MMAB, MMADHC, and MCEE genes are required for normal functioning of methylmalonyl CoA mutase.

Here, we report the case of a 5-years-old boy with MMA who presented with poor weight gain and recurrent episodes of fever, feeding problems, and; lethargy; since from the age of 11 months, and poor weight gain. This case is novel because we who was found that the patient had to have two previously unreported mutations in the *MUT* gene.

Commented [A 1]: Dear Authors,

Thank you for submitting your revised manuscript for editing. I have made changes to this manuscript for grammar, clarity, and readability. Do go through all my changes and comments carefully to ensure that I have retained your intended meaning, and do get back to me if you would like to clarify your intended meaning at any point. I have also checked the manuscript for conformance with the formatting guidelines provided and have checked the response letter. As always, please let me know if you have any further questions or concerns.

Commented [A 2]: Important:

1. As per the journal, units of measurement should be presented simply and concisely using System International (SI) units; please ensure that units are presented using the SI system at all instances.
2. References for some previously published data is missing. Please ensure that references are provided wherever required.
3. Informed consent from the patient is required and should be mentioned in the manuscript.

For more information, please refer to the guidelines at <https://www.hindawi.com/journals/crig/guidelines/>.

Commented [A 3]: As per the journal's guidelines, please provide email addresses of all the authors.

Formatted: Font: Bold

Formatted: Centered

Commented [A 4]: As per the journal's guidelines, the abstract is less than 200 words.

Formatted: Font: Bold

Formatted: Right: 0 cm, Space Before: 0 pt, Line spacing: single

Commented [A 5]: The significance of the recent developments in the patient's etiology is unclear; this sentence also breaks the flow of the abstract. Thus, I would suggest that you provide the importance of the developments in the patient, as it can confuse the readers.

Formatted: Normal

Commented [A 6]: Please clarify whether you mean recurrent episodes of lethargy, acidosis, hypoglycemia/hyperglycemia, and ketosis. If so, please rephrase as such for clarity.

Formatted: Font: Italic

Commented [A 7]: This part is unclear. How are mutations in these genes required for normal functioning of methylmalonyl CoA mutase? Please

2. Case Presentation

A 5-year-old boy ~~The child~~ presented for the first time at the age of 11 months, with complaints of fever, vomiting, poor feeding, and lethargy ~~since the age of 11 months~~. We observed that the patient ~~On examination he~~ had pallor and tachypnea and was drowsy. Laboratory tests suggested that the patient had ~~Further evaluation was suggestive of~~ high anion-gap metabolic acidosis with ketonuria (urine ketones 3+) ~~and with~~ normal electrolytes, blood sugar (94 mg/dL), vitamin B12, and homocysteine levels. Plasma ammonia ~~and plasma lactate were~~ 118 units, and ~~plasma lactate was~~ 2.9 units, respectively. ~~Transcranial magnetic simulation TMS results were~~ normal, but ~~urine-gas chromatography mass spectrometry (GC-MS) analysis of urine~~ revealed elevated 3-OH propionic acid [12.39 retention time (RT)] ~~and as well as elevated~~ methyl malonic acid levels [16.92 RT, Suppl Figure 1, in Supplementary Material available online at <https://doi.org/10.1155/2017/8984951>]. Since then, ~~the patient this child~~ was on a low-protein diet, carnitine, biotin, thiamine, and vitamin B12 injections; ~~he~~ Child was thereafter admitted to the hospital on ~~seven multiple occasions (7 times)~~ with acute decompensation and managed as per protocol. Mutational analysis ~~was sent for~~ MMA ~~which~~ showed a single heterozygous missense variant c.976 A>G (p.Arg326Gly) in exon 5 of the *MUT* gene (genomic coordinates: chr 6: 49421405); ~~as a~~ variant of uncertain significance. Chromosomal microarray analysis ~~done~~ did not reveal any major deletion or duplication ~~that which~~ could disrupt the gene. Since exon 3 and exon 6 were not adequately covered by next generation sequencing (NGS), further evaluation by Sanger sequencing for targeted exons was ~~performed done~~, and a ~~second 2nd~~ mutation in exon 3 c.753 G>A (p.=) was identified. The variants were ~~predicted found to be as~~ damaging by the ~~on~~-SIFT database ~~score~~ (Suppl data) ~~and as~~. They were also ~~predicted to be~~ deleterious by ~~on~~-Polyphen-2 and Mutation Taster, ~~but they were absent and not found~~ in the ExAC database. ~~Brain MRImagnetic resonance image brain of the patient~~ (done at the age of ~~four 4~~ years) ~~was showed ing~~ multifocal cystic encephalomalacic changes with surrounding gliosis in deep white matter predominantly in frontoparietal regions (Figure 1). ~~During in the~~ latest admission ~~of the patient to the hospital, we observed child was found to have~~ fresh neurological findings in the form of perioral tremors, generalizsed hypertonia, and generalizsed dystonia with clonus with exaggerated deep tendon reflexes. ~~The patient He~~ was treated with intravenous dextrose and sodium bicarbonate and was continued on carnitine and ~~injection of~~ vitamin B12 ~~injections~~. Plasma ammonia ~~and plasma lactate levels were~~ 18 units and ~~lactate level was~~ 4.9 units, respectively. ~~Brain magnetic resonance image MRI brain of the patient was repeated and~~ revealed bilateral basal ganglia hyperintensities, suggestive of metabolic stroke. After the subsidence of acute crisis, he was discharged on carnitine, ~~injection of~~ vitamin B12 ~~injections~~, and trihexyphenidyl. ~~The p~~Parents were counseled regarding ~~the patient's~~ prognosis and ~~possible for~~ prenatal diagnosis ~~for subsequent next~~ pregnancies.

Formatted: Space Before: 0 pt

Formatted: Font: Italic

Commented [A8]: You seem to have used both "variant of uncertain significance" and "variant of unknown significance" in the text. Please consider using either of the two terms for consistency.

Formatted: Indent: Left: 0 cm, Right: 0 cm, Space Before: 0 pt, Line spacing: single




Figure 1: The MRI brain magnetic resonance image of the 5-year-old boy with *MUT*-related methylmalonic acidemia (MMA) showing predominant frontoparietal abnormalities in the form of encephalomalacia and gliosis.

Formatted: Font: Italic

3. Discussion

The advent of NGS technology has enabled better characterization of mutations in several populations. In this study, we used NGS and Sanger sequencing to identify mutations in the genes linked to MMA development and revealed two novel variants of the *MUT* gene. In a Saudi study on 60 MMA patients of MMA, nonsense, missense, and frameshift mutations were detected across the *MUT* gene [3]. Another study in 43 Chinese patients identified 8 recurrent mutations and 10 novel mutations in the *MUT* gene [4]. A previous Indian study in 15 patients with clinically diagnosed MMA identified one novel exon 12 mutation in the *MUT* gene with predicted pathogenicity. Here, we identified two novel variants, one in exon 3 and another in exon 5 of the *MUT* gene, and both were labelled as variants of unknown significance (VUS). The exon 3 variant is a synonymous variant, and a different nucleotide change c.753 G>C (p.Lys251Asn) has been reported earlier in ClinVar. Some synonymous variants can also affect the splicing or protein function and lead to clinical phenotypes. The identified exon 5 variant is novel, but another close variant c.977 G>A (p.Arg326Lys) has been reported in ClinVar. The variants were found to be deleterious on bioinformatic analysis and were absent not found in the ExAC database. Both variants identified in the present case could be responsible for possibly explain the MMA phenotype of MMA in the child. *MUT*-related MMA has poor prognosis in most cases. Specialized diet and supplements may not improve the outcomes; even if MMA is diagnosed early. Early recognition and appropriate treatment of acute crises are necessary. Metabolic stroke can sometimes occur in the absence of acute metabolic decompensation; thus, so meticulous neurological examination at each visit is important useful. The treatment options for MMA include therapy include early liver transplantation [5]; and possibly gene therapy could also be used in the future. Genetic counseling and prenatal diagnosis could help these families of the patients in making informed reproductive decisions.

Formatted: Space Before: 0 pt

Commented [A9]: Do you mean in a study on Saudi patients? If so, please changed the highlighted part to "In a study on 60 Saudi patients of MMA."

Formatted: Font: Italic

Formatted: Font: Italic

Commented [A10]: Do you mean a study on 15 Indian patients? If so, please rephrase as "A previous study involving 15 Indian patients."

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Conflicts of Interest

The authors declare that ~~there is they have~~ no conflicts of interest ~~regarding the publication of this article.~~

Acknowledgments

The authors would like to acknowledge Dhiti Omics Tech-nologies Pvt Ltd for help in mutation ~~analysis.~~

References

- [1] K. Splinter, A.-K. Niemi, R. Cox et al., "Impaired health-related quality of life in children and families affected by methyl- malonic acidemia," *Journal of Genetic Counseling*, vol. 25, no. 5, pp. 936–944, 2016.
- [2] A. R. R. Devi and S. M. Naushad, "Targeted exome sequencing for the identification of complementation groups in methyl- malonic aciduria: a south Indian experience," *Clinical Biochem-istry*, vol. 50, no. 1-2, pp. 68–72, 2017.
- [3] F. Imtiaz, B. M. Al-Mubarak, A. Al-Mostafa et al., "Spectrum of mutations in 60 saudi patients with mut methylmalonic acidemia," *JIMD Reports*, vol. 29, pp. 39–46, 2016.
- [4] ~~L. S. Han LS, Z. Huang Z, F. Han F, et al., Ye J, Qiu WJ, Zhang HW, Wang Y, Gong ZW, Gu XF.~~ "Clinical features and MUT gene mutation spectrum in Chinese patients with isolated methylmalonic acidemia: identification of ten novel allelic variants," *World Journal of Pediatrics*, vol. ~~2015 Nov 1~~, no. 11(4), pp. ~~358–365~~, 2015.
- [5] M. Spada, P. L. Calvo, A. Brunati et al., "Liver transplantation in severe methylmalonic acidemia: the sooner, the better," *Journal of Pediatrics*, vol. ~~2015~~;167, pp. ~~1173~~, 2015.

Commented [A11]: The journal's preferred statement has been used.

Formatted: Space Before: 0 pt

Formatted: Space Before: 0 pt, Line spacing: single

Commented [A12]: As per the guidelines, a section titled "Supplementary Materials" should be included before the reference list with a concise description for each supplementary material file, if relevant. Supplementary materials are not modified by the journal's production team. Authors are responsible for providing the final supplementary materials files that will be published along with the article.

Formatted: Font: Bold

Formatted: Space Before: 0 pt, Line spacing: single

Commented [A 13]: The journal had no specific instructions regarding the format of the references; hence, I have formatted the references to maintain consistency and verified their accuracy.

Formatted: Font: (Default) Times New Roman

Formatted: Space Before: 0 pt

Formatted: Space Before: 0 pt, Line spacing: single

Formatted: Indent: Hanging: 0.5 cm, Space Before: 0 pt, Line spacing: single

Formatted: Font: Italic

Formatted: Font: Italic

The report presents an interesting case of methylmalonic acidemia (MMA) potentially caused by two newly identified mutations in the *MUT* gene. The study contributes to the array of mutations relevant to MMA and deserves publication. However, the manuscript has several flaws, which should be addressed before re-submission.

Major issues

Abstract: the background and clinical implications are missing.

In the background, the subject of the study should be introduced in 1-2 short sentences explaining what MMA is, including disease causes and clinical symptoms. The Abstract should end with the take-home message indicating the importance of genetic testing in cases suggestive of MMA; it should be patient-oriented rather than method-oriented. The statement that "With advent of NGS, judicious use of NGS with Sanger sequencing can help identify causative possibly pathogenic mutations" is trivial because it is obvious that without sequencing (either NGS or conventional Sanger), mutations cannot be identified; rather, it should be concluded that if MMA is suspected, genetic testing is necessary to identify the type of the disease, which would aid in applying the most appropriate treatment.

Response: As per the reviewer's suggestion, we added the following introductory sentences: "Methylmalonic acidemia (MMA) is a rare inherited metabolic disorder caused by deficiency of the enzyme methylmalonyl-CoA mutase. The disease is characterized in early infancy by lethargy, vomiting, failure to thrive, and encephalopathy and is fatal if left untreated." The conclusion of the abstract was modified as follows: "Our results indicate the necessity of genetic testing if MMA is suspected; it can confirm the diagnosis, aid in selecting treatment options, and may enrich the panel of responsible gene variants."

Introduction is totally missing.

Every case report must be preceded by a concise Introduction section (1-2 paragraphs) presenting the disease and stating the importance of the case. The Introduction should describe MMA as an inherited autosomal recessive disorder caused by deficiency in the conversion of methylmalonyl coenzyme A (CoA) to succinyl CoA, resulting in the accumulation of methylmalonic acid in the blood to toxic levels. The manifestations of the disease should be described, including symptoms, age at the onset, severity range, treatment algorithms, and prognosis. The frequency of this disorder in the general population should also be indicated.

In the next paragraph, the genetic spectrum of the disease should be characterized, including the affected genes and related metabolic changes. Thus, it should be mentioned that variants of the *MUT* gene encoding the enzyme methylmalonyl-CoA mutase are responsible for about 60% of MMA cases; *mut0* and *mut-* phenotypes caused by complete and partial enzyme deficiency, respectively, should be mentioned considering that the described case probably presented the *mut-* phenotype responsive to B12 supplementation. Variations in the *MMAA*, *MMAB*, *MMADHC*, and *MCEE* genes required for normal functioning of methylmalonyl CoA mutase should also be mentioned as they account for the rest of MMA cases.

Finally, the novelty of the present MMA case should be introduced by stating that the patient had two previously unreported mutations in the *MUT* gene.

Commented [A 14]: Dear Authors,

Thank you for sending in your responses to the reviewer comments for editing. I have edited the responses for language, checked that they adequately answer the reviewers' questions, and included comments where additional information is needed. I have also checked the manuscript to ensure that the required changes have been made to the manuscript and ensured consistency between the quoted text in the response letter and the corresponding text in the manuscript; **however, at most instances, I found that the revisions mentioned in the responses were not made in the manuscript. I have included comments to bring these instances to your attention.** Please ensure that the revisions suggested by the reviewer and mentioned in the responses are incorporated in the manuscript before submission. My best wishes for the submission of the revised manuscript!

Response: We thank the reviewer for the recommendation. Accordingly, in the revised manuscript, we have added the Introduction section wherein we have explained the genetic nature of MMA, mentioned the genes involved, and described the relevant biochemical mechanisms. Clinical manifestations, age at onset, incidence of the disease, and treatment regimens have also been described in this section. The presentation of the case has been justified by stating that our patient demonstrated MMA symptoms, which could have been caused by novel variants of the *MUT* gene.

Case presentation is incomplete.

The numerical value for high anion gap (mmol/L) should be shown.

Response: Thank you for pointing this out. In the revised manuscript, we have presented the results indicative of high anion gap.

Units for plasma ammonia and lactate should be provided. Currently, it is difficult to assess the status of these parameters as they can be expressed in conventional units or SI units; accordingly, the numerical values can differ. I recommend the authors to convert all test results to SI units for consistency and provide reference ranges for all biochemical parameters.

Response: As per your suggestion, we have converted the levels of plasma ammonia and lactate into SI units and have indicated the reference ranges.

Actual concentrations of propionic acid and methylmalonic acid should be provided.

Response: In the revised manuscript, concentrations of propionic and methylmalonic are provided.

It should be explained how the diagnosis of MMA was made and whether alternative diagnoses such as propionic acidemia were considered, as both conditions are manifested by ketones in the urine and high blood ammonia levels; furthermore, a high level of propionic acid was detected.

Response: The symptoms observed in the child (tachypnea, recurrent vomiting, poor feeding, lethargy) were characteristic of MMA and were confirmed by biochemical testing. Propionic acidemia was ruled out as we did not find mutations in the *PCC* genes, which encode propionyl-CoA carboxylase.

There is no explanation of specific treatment decisions. In particular, B12 injections should be justified, considering that there are two types of MMA differing in the sensitivity to cobalamin supplementation, responsive and nonresponsive, and that B12 levels in the patients were normal, i.e., there was no B12 deficiency.

Response: Patients with all forms of MMA (*mut0*, *mut-*, and *cbl* types) are routinely treated with a low-protein diet and respond well to carnitine supplements, as they typically develop carnitine deficiency. Our patient also had severe lactic acidosis, most likely due to thiamine deficiency, and elevated levels of propionic acid, which is indicative of dysfunctional propionyl-CoA carboxylase requiring biotin; therefore, he was administered thiamine and biotin. Although not all forms of MMA are responsive to cobalamin, we prescribed B12 supplements to the patient, as it is considered the first-line treatment for MMA.

NGS results: MMA is a recessive condition, i.e., only homozygous variants result in the phenotype, whereas heterozygous variants are asymptomatic. Therefore, the reported heterozygous missense variant c.976 A>G (p.Arg326Gly) in exon 5 of the *MUT* gene cannot be responsible for MMA in this patient. This fact should be discussed.

Commented [A 15]: Age at onset, incidence, relevant biochemical mechanisms and treatment regimens have not been discussed in the manuscript although your response mentions that these have been discussed in the Introduction.

Commented [A 16]: It is not clear in the manuscript which results are indicative of the high anion gap. Please mention this clearly.

Commented [A 17]: The changes mentioned in the response have not been made in the manuscript. Also, reference ranges for other parameters, as suggested by the reviewer are not mentioned in the revised manuscript. Please ensure that these changes are made.

Commented [A 18]: Though you have mentioned in the response that the concentrations have been provided in the manuscript, they have not been indicated. Please provide the concentrations before submission of the revised version of the manuscript.

Commented [A 19]: The reviewer has suggested that the diagnosis of MMA should be explained; hence, I would suggest that you add this explanation in the manuscript to enhance the impact of this case study and describe what exactly you mean by biochemical testing.

Commented [A 20]: I would suggest that you add this explanation in the manuscript to clearly communicate the difference between the two types of MMA to the reader.

Response: According to the recommendation of the reviewer, we have added the following sentences: "Since MMA is a recessive autosomal disorder, the newly found heterozygous missense variant in exon 5 of the *MUT* gene cannot be responsible for the symptoms of the patient. However, it is known that over 180 missense mutations in the *MUT* gene have been linked to the severe (mut0) MMA form; therefore, the newly identified missense mutation should be further investigated for its functional significance."

Line 45: The test results of plasma ammonia and lactate should be converted to the SI units and interpreted. Plasma ammonia levels significantly decreased but lactate levels increased in parallel with deterioration of neurological conditions of the patient.

Response: According to the recommendations of the reviewer, we have mentioned in the manuscript that plasma ammonia level significantly decreased, whereas plasma lactate level increased as compared to that in the original test results, and the overall condition of the patient worsened.

Lines 50-51: What was the prognosis for this patient? It should be indicated. Considering that the parents must be carriers of the MMA-causing mutation(s), were they asked to undergo genetic testing?

Response: Monitoring of the patient for several years – from 11 months to 5 years – revealed the progression of the disease. This was evident from the appearance of additional neurological symptoms at the age of 4 years; therefore, the prognosis was not favorable. We recommended the parents to undergo genetic testing and counseling before considering the next pregnancy. This information has been added to the revised manuscript.

Lines 52-55: This paragraph describing MMA should be moved to the Introduction.

Response: We thank the reviewer for the recommendation. The paragraph has been modified and moved to the Introduction.

Lines 61-64: The description of comparative advantages of NGS and Sanger sequencing is trivial and not directly relevant to the subject of the case report, which is identification of new mutations relevant to MMA. This paragraph should be reduced to the statement that the mutations were identified by NGS as well as by Sanger sequencing.

Response: According to the recommendation of the reviewer, this part was shortened as follows: "In this study, we used NGS and Sanger sequencing to identify mutations in the genes linked to MMA development and revealed two novel variants of the *MUT* gene."

Line 77: The variant in exon 5 is heterozygous and cannot be responsible for MMA symptoms as MMA is a recessive inheritance pattern and the mutation should be homozygous to cause the phenotype. The statement regarding the exon 5 variant should be corrected.

Response: We modified the sentence as follows: "Since MMA is a recessive autosomal disorder, the newly found heterozygous missense variant in exon 5 of the *MUT* gene cannot be responsible for the observed clinical manifestations. However, it is known that over 180 missense mutations in the *MUT* gene have been linked to the severe (mut0) MMA form (Keyfi et al., 2016); therefore, this variant should be further investigated in *in vitro* and *in vivo* models to determine its functional effects."

Implications of the study based on the specific findings of this case should be mentioned.

How does the case contribute to the diagnosis and treatment options of MMA?

Response: Analysis of this case revealed that although the identified mutations do not seem

Commented [A 21]: These statements have not been included in the manuscript. Please ensure that this is done prior to resubmission.

Commented [A 22]: The response does not match the requirement of the reviewer, as you have not converted the test results of plasma ammonia and lactate to SI units in the manuscript. Also, the revised manuscript does not mention that "plasma ammonia level significantly decreased, whereas plasma lactate level increased as compared to that in the original test results, and the overall condition of the patient worsened." Please ensure that this information is added to the manuscript.

Commented [A 23]: The highlighted part has not been added in the manuscript; however, it is mentioned in the response that it has been added. Please ensure that this information is added to the manuscript.

Commented [A 24]: These modifications have not been made in the manuscript. Please make these modifications in the manuscript before submission.

to cause severe deficiency in the production of any functional enzyme linked to MMA pathogenesis, the symptoms presented by the patient are serious and the prognosis is not favorable, suggesting that the genotype and clinical phenotype associated with MMA are not always concordant. Nevertheless, in cases when MMA is suspected, genetic testing is important to confirm the diagnosis and the most appropriate treatment should be prescribed.

[These considerations have been added at the end of the Discussion.](#)

5. The language is poor. There are multiple grammar and stylistic mistakes, which must be corrected. The spelling should be consistent either with the American or British English but not be the mixture of the two.

[Response: The manuscript has been revised by a professional English-speaking editor and all language-related errors have been corrected.](#)

Minor issues:

- All abbreviations must be defined at the first mention both in the Abstract and the main text.

[Response: All abbreviations have been defined, as recommended.](#)

- Gene symbols (*MUT*) should be italicized.

[Response: In the revised manuscript, all gene symbols are italicized.](#)

Commented [A 25]: This information has not been added at the end of the Discussion. Please ensure that this is added in the manuscript.

Physical Science Sample

Structural Prediction prediction of Bisbis(di-p-anisole)-1,4-azabutadiene-bis[triphenylphosphine]ruthenium(II) complex Using using ³¹P NMR Spectroscopy spectroscopy

Author Details

Abstract¹

~~In this study, The present paper reports the use of ³¹P NMR spectroscopy to predict the isomer structures of [bis-4-methoxy-phenyl-[3-(4-methoxy-phenyl)-allylidene]-amino]-bis[triphenylphosphine]ruthenium(II) complex, also known as bis(di-p-anisole)-1,4-azabutadiene-bis[triphenylphosphine]ruthenium(II) complex, was synthesized using: The complexation reaction was carried out (di-p-anisole)-1,4-azabutadiene (compound 1), triphenylphosphine, and ruthenium chloride in 2:2:1 ratio under refluxing conditions of (di-p-anisole)-1,4-azabutadiene (compound 1), triphenylphosphine (PPh₃), and ruthenium chloride in the ratio of 2:2:1 for five 5 hours. The formation of the In addition, ruthenium(II) complex were was confirmed by also characterized using FTIR and UV-Vis spectroscopic analyse to support the formation of ruthenium(II) complexes. ³¹P NMR spectroscopy pic study on ruthenium(II) complexes suggested indicated the presence of that there are three isomers present after the complexation reaction. All the isomers of the ruthenium complex had demonstrate octahedral geometry.~~

Keywords: ³¹P NMR spectroscopy; FTIR spectroscopy; UV-Vis spectroscopy; Ru complex; Isomers; Structure prediction

¹ NMR, nuclear magnetic resonance; FTIR, Fourier transform infrared; UV-Vis, ultraviolet-visible

Commented [A1]: Thanks for providing this opportunity to assist you with this manuscript. I have edited the text for language, grammar, and improved clarity, while also ensuring logical flow and proper structure. I have also checked the manuscript for conformance with the formatting guidelines for Inorganic Chemistry Communications provided at

<https://www.elsevier.com/journals/inorganic-chemistry-communications/1387-7003/guide-for-authors#25000>

In addition, I have crosschecked your responses to the reviewer comments with the changes in the manuscript. Please refer to my detailed comments in the response file. In the cases where additional information is required from you, I have added comments to bring them to your attention.

Should you have any questions, please feel free to get back to me.

My best wishes for your success with the manuscript.

Formatted: Not Highlight

Formatted: Not Highlight

Commented [A2]: I have added this to ensure a complete description of the compound.

Commented [A3]: Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lower-case superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each

Commented [A4]: I have revised the introductory sentence as the information is already present later in the abstract. Moreover, other spectroscopic techniques were

Commented [A5]: The aim of this study must be specified in the abstract. Precisely, why was this particular reaction chosen? Do the products have any practical applications?

Formatted: Font: Italic

Formatted: Font: Bold

Commented [A6]: Both *refluxing conditions* and *reflux conditions* are acceptable in this context, but I have used the latter consistently in the text.

Commented [A7]: I have defined all the abbreviations in a footnote on this page, as per the journal guidelines.

Commented [U8]: Dear Editor, my new revisions are in red font in this file.

Commented [A9]: It seems that there is only *one complex* (synthesized from the same starting materials) that has

Formatted: Justified, No widow/orphan control

Commented [A10]: A *Graphical abstract* is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of

Commented [A11]: I have provided the keywords for you. Please check if they are acceptable.

1. Introduction

Nuclear magnetic resonance (NMR) spectroscopy is an essential instrument-analytical tool in the field of chemistry as it can help determine-elucidate the structure of a molecule, identify-detect the presence of impurities in a sample, and determine the rates-of formation and-as-well-as degradation of a compound. Even in 1970s, NMR has been used as early as in the 1970s already been used to determine-detect the cancer formation which had been identified to be offered a simple, fast, and low-cost method to-for this purpose identify-cancer formation [1-3].

For inorganic chemists commonly use, using of ^{31}P NMR spectroscopy to identify the structures of a complexes containing phosphine ligands is very common [4, 5]. For example, the well-known examples is the use of ^{31}P NMR spectroscopy to determine the mechanism of Wilkinson hydrogenation was determined by ^{31}P NMR spectroscopy, mechanism-based on by identifying the coupling patterns among the phosphine ligands as well as those and also the coupling constants between the phosphine ligands as well as and the rhodium(I) metal centre/center [6].

In As part of our long-term research interest-on the synthesis of in-ruthenium(II) complexes-synthesis, we used the (di-*p*-anisole)-1,4-azabutadiene (**1**) and triphenylphosphine (PPh_3) as the ligands to-for reaction react with ruthenium trichloride under reflux conditions. The structures of the products- resulting complexes were formed- were checked-identified by using ^{31}P NMR spectroscopy, FTIR spectroscopy, and UV-Vis spectroscopy and the results found in the spectra are worth to be discussed in the present communication. For inorganic chemist, using of ^{31}P NMR to identify the structure of a complex containing phosphine ligands is very common [4, 5]. The well-known examples is the use of ^{31}P NMR spectroscopy to determine the Wilkinson hydrogenation mechanism by identifying the coupling patterns among phosphine ligands and also the coupling constants between phosphine ligands as well as rhodium(I) metal centre [6].

2. Methodology

The ruthenium complexes were characterized using UV/Vis, FTIR, and ^{31}P NMR spectroscopy. The IR spectra were recorded using-on a Thermo Scientific Nicolet iS10 spectrophotometer in-using KBr disc. The ^1H NMR spectrum for-of compound **1** and ^{31}P NMR spectrum for-of the ruthenium(II) complexes were recorded using-on a JEOL JNM-ECA 500 spectrometer with TMS as an-the internal standard. The absorption spectra was/were recorded with-on a Jasco V-630 UV-Vis spectrophotometer.

2.1. Preparation of (4-Methoxy-phenyl)-[3-(4-methoxy-phenyl)-allylidene]-amine or (di-*p*-Anisole)-1,4-azabutadiene (**1**)

4-Methoxycinnamaldehyde (1.62 g, 10.00 mmol) was dissolved in 10 mL of ethanol, and followed by the addition of 4-methoxyaniline (1.23 g, 10.00 mmol) which was then added to solution. The reaction mixture was stirred for 4 hours and to obtain a resulted in green-yellow solid, which The solid was filtered, washed with 5 mL of ethanol, and dried *in vacuo*. The solid was purified by dissolving it in DCM and then layered with hexane via slow diffusion to yield compound **1**. Yield: 2.368 g (88.7%); IR (KBr, cm^{-1}): 3036 (C-H stretching), 1627 (C=N- stretching), 1601 (C=C stretching, aliphatic), 1575 and 1468 (C=C stretching, aromatic), and 1110 (OCH_3 stretching); ^1H NMR (500 MHz, CDCl_3): δ : 8.25 (d, 1H, Hz, -CH=N-), 7.47 (d, 2H, Hz-), 7.18 (d, 2H, Hz-), 7.05 (t, 1H, Hz, H-C α), 6.99 (m, 1H, H-C β), 6.90 (d, 4H, Hz-), 3.83 (s, 3H, OCH_3), and 3.81 (s, 3H, OCH_3); UV-Vis (DCM, /nm): 273, 373; Anal. Calc. for $\text{C}_{17}\text{H}_{17}\text{O}_2\text{N}$ (%): C, 76.38; H, 6.41; N, 5.24; Found (%): C, 76.75; H, 6.31; N, 5.05.

2.2. Preparation of [Bis(4-methoxy-phenyl)-[3-(4-methoxy-phenyl)-allylidene]-amino]-bis[triphenylphosphine]ruthenium(II) or Bis(di-*p*-anisole)-1,4-azabutadiene]-bis[triphenylphosphine]ruthenium(II) Complexes

For the synthesis of bis(di-*p*-anisole)-1,4-azabutadiene-bis[triphenylphosphine]ruthenium(II) complex, $\text{RuCl}_3 \cdot x\text{H}_2\text{O}$ (2.070 g, 1.0 mmol) and PPh_3 (0.525 g, 2.0 mmol) were added to a round-bottom flask containing 10 mL ethanol, and the mixture was then refluxed for 5 h. Compound **1** (0.316 g, 2.0 mmol) was then added to the round-bottom flask, and the mixture was refluxed for another 5 h. The resulting pale-maroon solids were formed, filtered and washed with hexane, and the precipitate was dried *in vacuo*: IR (KBr, cm^{-1}): 3034 (C-H stretching), 1661 (C=N), 1576 (-merged IR band of-for aliphatic and aromatic C=C stretching from aliphatic and aromatic), 1469 (C=C stretching of aromatic ring), and 654 (Ru-C), and

Commented [A12]: I have deleted the section heading as the Introduction, Experimental, Results and Discussion sections should be combined into a single untitled section.

Commented [A13]: The objective of the current study is not clear from the introduction. Please state a sound reason for the interest in synthesis of ruthenium(II) complexes. Also, please explain why the structure elucidation of these complexes is so important.

Commented [A14]: I made this change as spectroscopy is a method/tool, and not an instrument.

Commented [A15]: The in-text citations are in the style prescribed by the journal.

Commented [A16]: In the present study, a Ru(II) complex is synthesized, the complexation is confirmed by UV-vis and FTIR spectroscopies, and the isomers are identified by NMR spectroscopy. In general, this is a study on the synthesis and characterization of the complex by different techniques, and NMR is alone is not discussed exclusively (and neither in detail). Hence, suggest that the introduction be made more general. The focus should be on the importance of these complexes and the criticality of their structural elucidation rather than on NMR. Along with NMR, a brief description of UV-Vis and FTIR can also be included.

Commented [A17]: Please check if you mean "constants" here as well.

Commented [A18]: I have shifted this paragraph here for better flow and continuity of text.

Formatted: Font: Italic

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Italic

Formatted: Font: Bold

Commented [A19]: Though you have included the duration, but the information on the stirring speed and temperature has not been included in the manuscript. I recommend including this information here.

Formatted: Font: Italic

Formatted: Font: Bold

Formatted: Font: Italic

Commented [A20]: The information here may be a little difficult to follow; I recommend presenting this in the form of a table to improve readability.

Formatted: Font: Italic

Formatted: Font: Bold

Formatted: Font: Italic

577 (Ru-N); ^{31}P NMR (202.5 MHz, CDCl_3) δ : 49.7 (d, 1P, Hz), 47.4 (d, 1P, Hz), 41.7 (d, 1P, Hz), 39.7 (d, 1P, Hz), 35.1 (s, $\text{Ph}_3\text{P}=\text{O}$), and 29.9 (s, 1P); UV-Vis (DCM) (λ): 321 and 382.

On the other hand, the binding of compound **1** to the ruthenium(II) metal center was confirmed using FTIR and UV-Vis spectroscopies. The comparing the IR spectra between of compound **1** and the ruthenium complexes (Figure 4) reveals that the vibrations of C=N and C=C stretching bands are shifted with respect to those in **1**, thereby confirming the binding of **1** to the ruthenium(II) metal center. The C=N stretching band is blue-shifted from 1627 cm^{-1} in the spectrum of compound **1** to 1661 cm^{-1} in the spectrum of the ruthenium complex [97, 108]. In contrast, whereas the C=C stretching IR band appears at 1601 cm^{-1} in the spectrum of compound **1** but it is not clearly shown in the spectrum of the complex, because the IR bands of aliphatic and aromatic C=C bands for aliphatic and aromatic were merging into one a single broad IR band centered at 1576 cm^{-1} . Nevertheless, the two additional IR peaks are present at 577 and 654 cm^{-1} in the fingerprint region of the spectrum at 577 and 654 cm^{-1} , indicating the formation of the respective Ru-N and Ru-C bonds [49].

Figure 4: IR spectra of (a) compound **1** and (b) ruthenium(II) complexes.

The complexation of compound **1** to the ruthenium(II) metal center is further supported by the UV-Vis data spectra as shown in Figure 5. For in the case of compound **1**, two absorption bands were observed at 273 and 372 nm, which are assigned to the transitions of the benzene ring and imine group [210], respectively. After the complexation, both the absorption bands undergo significant bathochromic shifts to 321 and 382 nm, respectively, thereby confirming the binding of **1** to the ruthenium(II) metal center via the nitrogen atom from the C=N group and the carbon atom from the aliphatic C=C group in of the C=C-N moiety. The bathochromic shifts of these two absorption bands were due attributed to the backbonding of electrons from Ru to the antibonding orbitals of the C=C-N moiety in compound **1**. This backbonding, in turn, weakens the bonds in C=C-N [113].

Figure 5: UV-Vis spectra of (a) compound **1** and (b) ruthenium (II) complex.

3. Results and Discussion

Characterization of the ruthenium complexes was done using UV/Vis, FTIR, and ^{31}P NMR spectroscopy. The IR spectra was found by Thermo Scientific Nicolet iS10 in KBr disc. ^1H NMR spectrum for compound **1** and ^{31}P NMR spectrum for ruthenium(II) complexes obtained through JEOL JNM-ECA 500 spectrometer with TMS as an internal standard. The absorption spectra recorded with Jasco V-630 spectrophotometer.

Once the complexation was confirmed, as discussed above, the ^{31}P NMR spectrum of the ruthenium complex (Fig. 3) was analyzed for its detailed structural elucidation. The ^{31}P NMR spectrum of the product shows appearance of two pairs of doublets and one singlet, indicating in the ^{31}P NMR spectrum for ruthenium complexes (Figure 1) indicate the formation of that there are three isomers (1:1:1 ratio) present as a result of the complexation reaction with the ratio of 1:1:1.

Figure 3: ^{31}P NMR spectrum for ruthenium(II) complexes.

The singlet at 29.88 ppm reveals that the two PPh_3 units are magnetically equivalent in the ruthenium(II) complex. There can be three possible structures based on this singlet. In the first case, the two PPh_3 units are either located at the axial positions of an octahedron and are trans to each other (Figure 2(a)) [127], while in the other two cases, they are located on the equatorial plane, which is only trans to either one of the C atoms from the C=C bond (Fig. 4(b)) or the N atom from the N=C bond (Figure 4(c)). The presence of the two PPh_3 units at the axial positions corresponds to the trans isomer shown in Figure 2(a) is a trans isomer (Fig. 4(a)), whereas the presence of these units at the equatorial positions corresponds to the two isomers in Figures 2(b) and 2(c) are cis isomers (Fig. 2(b) and 2(c)). Unfortunately, at this stage, we cannot identify which one is the correct structure represented based on by the singlet at 29.88 ppm at this stage.

Formatted: Font: Italic

Commented [A21]: Please update the missing information.

Commented [A22]: I have made some heavy changes to the flow of the text here. We first confirm if the complexation reaction has occurred (using UV-vis and IR spectroscopies) and then we proceed to elucidate the structure of the complex (NMR). Hence, the UV-vis/IR studies have been moved to be presented before the NMR studies.

Formatted: Font: Bold

Commented [A23]: I have updated the figure numbers in the order of their appearance in the manuscript, as I have rearranged the text.

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Commented [A24]: The mention of these references here is not clear. This result is also found in the current study. Please clarify what these references exactly refer to.

Commented [A25]: Since I have moved the text, I have updated the reference numbers in the order of their appearance. I have also updated the reference list accordingly.

Formatted: Font: Bold

Commented [A26]: I used this word as the fingerprint region is unique to each compound and the peaks in this region are typically used for confirming the structure of a compound.

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Commented [A27]: Please check if the edit is correct.

Formatted: Font: Bold, Font color: Red

Commented [A28]: The text you have included here only partially addresses comment 4. Please check my comments in the response file and do get back to me so that I can suitably revise it for you, if needed.

Formatted: Font: Bold

Commented [A29]: The text repeats information presented in an earlier paragraph. Therefore, I have deleted this to avoid repetition.

Commented [A30]: I have added this sentence to ensure a logical flow and connectivity in the text.

Commented [A31]: Please check if this insertion is acceptable. I have included this based on the information ...

Commented [A32]: Changes were made here to improve ...

Figure 24: Postulated structures of (a) *trans*- and (b) and (c) *cis*-[bis(*di-p*-anisole)-1,4-azabutadiene]-bis[triphenylphosphine]ruthenium(II).

Meanwhile, a pair of doublets at 41.84 and 39.74 ppm with a J -coupling constant of 21 Hz is assigned to the *cis*-isomer of the ruthenium(II) complex as shown in Figure 3(a). The other pair of doublets at 49.80 and 47.36 ppm with a coupling constant of 38 Hz is assigned to the *trans*-ruthenium(II) complex shown in Figure 3(b). It is evident that the difference in the coupling constants between the ruthenium(II) complexes arises in Figures 3(a) and 3(b) is due owing to the positions of the PPh₃ ligands. The doublet with a smaller coupling constant (i.e., 21 Hz) is assigned to the *cis*-isomer because both the PPh₃ ligands are in the equatorial plane. The presence of doublets originate because the J -coupling constants in the complex is shown in Figure 3(a) because both PPh₃ ligands are *trans* to different atoms, that is, (nitrogen and carbon) atoms. In the ruthenium(II) complex shown in Figure 3(b), the two PPh₃ ligands are located at the axial positions and are *trans* to each other. Unlike the *trans* complex in Figure 24(a), the magnetic fields of these two PPh₃ units in the complex shown in Figure 3(b) are different because the two ligands of (*di-p*-anisole)-1,4-azabutadiene ligands are *trans* to each other at on the equatorial plane (Figure 3(b)). The single peak observed at 35.14 ppm is attributed to the presence of the triphenylphosphine oxide [138]. All the isomers of the ruthenium complex had octahedral geometry.

Figure 35: Postulated structures of (a) *cis*- and (b) *trans*-[bis(*di-p*-anisole)-1,4-azabutadiene]-bis[triphenylphosphine]ruthenium(II).

On the other hand, the binding of compound 1 to ruthenium(II) metal centre can be confirmed using FTIR and UV-Vis spectroscopy. Comparing the IR spectra between compound 1 and ruthenium complexes (Figure 4), the vibrations of C=N and C=C stretching bands have been shifted after binding to ruthenium(II) metal centre. For C=N stretching band, it shifted from 1627 cm⁻¹ in compound 1 to 1661 cm⁻¹ in ruthenium complex [9, 10], whereas for C=C stretching, the IR band appears at 1601 cm⁻¹ in compound 1 but it is not clearly shown in the complex because the IR bands of C=C bands for aliphatic and aromatic were merging into one broad IR band centred at 1576 cm⁻¹. Nevertheless two additional IR peaks are present in the fingerprint region at 577 and 654 cm⁻¹ indicating the formation of respective Ru-N and Ru-C bonds [11].

Figure 4: IR spectra of compound 1 (a) and ruthenium(II) complexes (b).

The complexation of compound 1 to ruthenium(II) metal centre can be further supported by the UV-vis data as shown in Figure 5. For compound 1, two absorption bands were observed at 273 and 372 nm which are assigned to transition of the benzene ring and transition of the imine group [12], respectively. After the complexation, both absorption bands shifts to 321 and 382 nm, respectively. Significant shifts of these two absorption bands have proven compound 1 was successfully bound to ruthenium(II) metal centre via the nitrogen atom from C=N group and carbon atom from C=C aliphatic group in C=C-C=N moiety. The bathochromic shift of these two absorption bands was due to the backbonding of electrons from Ru to the antibonding orbitals of C=C-C=N moiety in compound 1. This, in turn, has weakened the bond in C=C-C=N [13].

Figure 5: UV-Vis spectra of compound 1 (a) and ruthenium(II) complex (b).

In addition, the data from IR and UV-Vis revealed the successful binding of compound 1 has bound to the ruthenium(II) metal centre was confirmed from the IR and UV-Vis spectral data.

4. Conclusion

The ³¹P NMR spectra revealed the evidence from ³¹P NMR spectrum has shown the presence of three isomers of the bis(*di-p*-anisole)-1,4-azabutadiene-bis[triphenylphosphine]ruthenium(II) complex in the 1:1:1 ratio of 1:1:1. Two of the three isomers are those shown in Fig. 5, i.e., one *cis* and one *trans* isomer, while the third isomer could be any one of those shown in Fig. 4. In addition, the data from IR and UV-Vis revealed that compound 1 has bound to ruthenium(II) metal centre.

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic, Font color: Red

Commented [A33]: The figure number has already been mentioned previously.

Commented [A34]: I have included this sentence here too, as this is mentioned in the abstract.

Formatted: Font color: Red

Formatted: Font color: Red

Formatted: Font color: Red

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Italic

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Commented [A35]: I have shifted this section before the NMR studies to improve the flow of the text.

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Italic

Commented [A36]: I have added this sentence as a final concluding statement. However, the conclusion should be improved further; please go through my previous comment.

Commented [A37]: The conclusion needs further improvement. The future prospect of the study must be clearly specified. In addition, where can the information presented herein be utilized? Will it help in the structure elucidation of other relevant Ru-phosphine complexes?

Formatted: Font: Bold

References

1. R. Damadian, "Tumor detection by nuclear magnetic resonance," *Science*, vol. 171, no. 3976, (1971) pp. 1151–1153, 1971. <https://doi.org/10.1126/science.171.3976.1151>
2. I.-D. Weisman, L.H. Bennett, L.-R. Maxwell Sr., D.-E. Henson, "Cancer detection by NMR in the living animal," *Journal of Research of the National Bureau of Standards Section A: Physics and Chemistry*, vol. 80, no. 3, (1976) pp. 439–450, 1976. <https://doi.org/10.6028/jres.080a.048>
3. S. Tiziani, V. Lopes, and U.-L. Günther, "Early stage diagnosis of oral cancer using ¹H NMR-Based metabolomics," *Neoplasia*, vol. 11, no. 3, (2009) pp. 269–276, 2009. <https://doi.org/10.1593/neo.81396>
4. D.-G. Gorenstein, "Non-biological aspects of phosphorus-31 NMR spectroscopy," *Progress in Nuclear Magnetic Resonance Spectroscopy*, vol. 16, (1984) pp. 1–98, 1984. [https://doi.org/10.1016/0079-6565\(84\)80002-3](https://doi.org/10.1016/0079-6565(84)80002-3)
5. P.S. Pregosin, and R.-W. Kunz, ³¹P and ¹³C NMR Spectroscopy of Transition Metal Complexes, Springer, Heidelberg, Germany, 1979. <https://doi.org/10.1007/978-3-642-48830-6>
6. P. Meakin, J.-P. Jesson, and C.-A. Tolman, "Nature of chlorotris(triphenylphosphine)rhodium in solution and its reaction with hydrogen," *Journal of the American Chemical Society*, 94, (9) (1972) pp. 3240–3242, 1972. <https://doi.org/10.1021/ja00764a061>
7. N. Dharmaraj, P. Viswanathamurthi, K. Natarajan, "Ruthenium(II) complexes containing bidentate Schiff bases and their antifungal activity," *Transition Metal Chemistry*, vol. 26, No. 1-2, pp. 105–109, 2001.
8. V.V. Grushin, C. Bensimon, H. Alper, "Potassium complexes containing both crown ether and tertiary phosphine oxide ligands," *Inorganic Chemistry*, vol. 32, no. 3, pp. 345–346, 1993.
9. N. Ahmed, M. Riaz, A. Ahmed, and M. Bhagat, "Synthesis, characterisation, and biological evaluation of Zn(II) complex with tridentate (NNO Donor) Schiff base ligand," *International Journal of Inorganic Chemistry*, vol. 2015, (2015), Article ID 607178, 5 pages, 2015. <https://doi.org/10.1155/2015/607178>
10. N. Bharti, Shailendra, S. Sharma, F. Naqvi, and A. Azam, "New palladium(II) complexes of 5-nitrothiophene-2-carboxaldehyde thiosemicarbazones: Synthesis, spectral studies and in vitro anti-amoebic activity," *Bioorganic & Medicinal Chemistry*, vol. 11, no. 13, (2003) pp. 2923–2929, 2003. [https://doi.org/10.1016/s0968-0896\(03\)00213-x](https://doi.org/10.1016/s0968-0896(03)00213-x)
9. N.-H. Al-Sha'alan, "Antimicrobial activity and spectral, magnetic and thermal studies of some transition metal complexes of a Schiff base hydrazone containing a quinoline moiety," *Molecules*, vol. 12, no. 5, (2007) pp. 1080–1091, 2007. <https://doi.org/10.3390/12051080>
10. P. Jayaseelan, S. Prasad, S. Vedanayaki, and R. Rajavel, "Synthesis, characterization, antimicrobial, DNA binding and cleavage studies of Schiff base metal complexes," *Arabian J. Chemistry*, 9, (2011) S668–S677. <https://doi.org/10.1016/j.arabjoc.2011.07.029>
11. M.-G. Tay, Z. Ngaini, M.A.M. Arif et al., "Complexation of bis-2-(benzylideneamino)phenol to cobalt(II) and zinc(II), and their spectroscopic studies," *Borneo Journal of Resource Science and Technology*, vol. 3, no. 1, (2013) pp. 26–34, 2013. <https://doi.org/10.33736/bjrst.253.2013>
12. N. Dharmaraj, P. Viswanathamurthi, K. Natarajan, "Ruthenium(II) complexes containing bidentate Schiff bases and their antifungal activity," *Transition Metal Chemistry*, vol. 26, No. 1-2, (2001) pp. 105–109, 2001. <https://doi.org/10.1023/a:1007132408648>
13. V.V. Grushin, C. Bensimon, H. Alper, "Potassium complexes containing both crown ether and tertiary phosphine oxide ligands," *Inorganic Chemistry*, vol. 32, no. 3, (1993) pp. 345–346, 1993. <https://doi.org/10.1021/ic00055a021>
- 15.

HIGHLIGHTS

- Three isomers were detected for a phosphine-bearing Ru complex using ³¹P NMR.
- Formation of Ru-N and Ru-C bonds were confirmed by FTIR spectroscopy.
- At least one cis isomer and one trans isomer of the complex were formed.

Commented [A38]: I have checked all the references for their accuracy and have formatted them as per the journal style.

I have also added the DOI for all the references, as per the journal guidelines.

Field Code Changed

Commented [A39]: I have updated the reference list as per the changes in the text.

Commented [A40]: I have added the volume number and page number for this reference.

Formatted: No bullets or numbering

Commented [A41]: Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. Highlights should be submitted in a separate editable file in the online submission system.

Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

I have prepared the highlights for you. Please go through them and check if they are acceptable. (Please remember to move them to a separate file before submission, as mentioned above).

Formatted: Superscript

Formatted: List Paragraph, Bulleted + Level: 1 + Aligned at: 0.63 cm + Indent at: 1.27 cm

RESPONSES TO REVIEWER COMMENTS

This is a relatively simpler and brief report on structure identification of an organometallic complex using ^{31}P NMR. There are certain missing gaps in this study. Though the topic of the study fits into the scope of the journal, I do not recommend its publication in the current form, however, the manuscript can be reconsidered for the same after major revisions.

Response: We thank you for your thoughtful suggestions and insights; the manuscript has benefited from these insightful suggestions. We have rechecked the manuscript and made the necessary changes in accordance with your suggestions (the revised portions have been marked in red font in the revised manuscript). Our responses to your comments are given below.

1. Some information is missing in experimental section describing the syntheses of compound 1 and the Ru complex. Details on the stirring of the reaction mixture are not complete. Particularly, the duration and temperature of stirring is critical in many syntheses, and this should be precisely mentioned for the easy reproducibility of experimental data. And, was the yield or nature of the product affected by the stirring speed/temperature/reaction time?

Response:

Thank you for noting this critical point. The reaction mixture for the synthesis of compound 1 was stirred for 4 h, while that for the synthesis of the Ru complex was stirred for 5 h. In both the cases, the temperature was maintained at 60 °C. Two different stirring speeds (250 and 150 rpm) were tested for both the reaction mixtures. However, no significant difference in the yield or nature of the products was observed.

2. Corresponding to the singlet at 29.88 ppm, the authors mention the existence of two probable structures, i.e., a structure in which phosphines are located at the two axial positions or a structure in which the phosphines are located on the equatorial plane and are trans to the carbon atom from C=C. I think there could be another probable structure corresponding to this peak: a structure in which phosphines are located on the equatorial plane but are trans to N=C bonds. Please discuss this aspect.

Response:

Thank you for your insightful comments. We analyzed the spectrum again and found that the peak at 29.88 ppm could also correspond to a structure in which the phosphines are on the equatorial plane and trans to N=C. This corresponds to a cis configuration of the complex. We have now included this in the manuscript and also in Fig. 2. However, we still cannot assign any specific structure based on this singlet.

3. In the structures shown in Figure 2a and Figure 3b, the two phosphine ligands are trans to each other. Despite of this, only one peak is observed for the former, while a doublet is found for the latter. Please clarify this.

Response:

We thank you for this valuable comment. The magnetic fields of the two phosphine ligands shown in Fig. 3b are different because the two (di-*p*-anisole)-1,4-azabutadiene ligands are trans to each other on the equatorial plane. That is, the phosphine ligands shown in Fig. 2a are magnetically equivalent, while the ones shown in Fig. 3b are not. Thus, a singlet is observed for the former, while a doublet is observed for the latter. This aspect has now been discussed in the revised manuscript.

4. What solvent did the authors used for UV-vis spectroscopy? Although, bathochromic shift confirmed the bond formation to the metal center, authors have to mention probable reason for such a bathochromic shifting, particularly in the terms of electronic distribution. In addition, the shift of the first peak (273 nm to 321 nm) was significantly high than that of second peak (372 to 382 nm). Can authors give probable reason for this based on the bond formation to the metal center?

Response:

All the samples for the UV-Vis spectroscopic measurement were prepared in water. After a careful survey of the literature, we have concluded that the bathochromic shift resulted from the backbonding of electrons from Ru to the antibonding orbitals of C=C-C=N in compound 1. That is, the addition of electrons to the antibonding orbitals weakens the C=C-C=N bonds, leading to the bathochromic shift. We have now discussed this aspect in the revised manuscript.

Commented [A42]: I have crosschecked all the responses to the reviewer comments and the changes in the manuscript. I found that some of the comments were not completely addressed, while the changes pertaining to some of the comments have been addressed in the responses but have not been incorporated in the manuscript. I have flagged all such instances through comments for your consideration. Please do go through them and do get back to me, so that I can revise the text for you if needed.

Commented [A43]: Although the information on the duration of the reaction has been added in the revised manuscript, the information on stirring speed and temperature is not included. I recommend including this in the manuscript. Please do get back to me if you need my assistance with this.

Commented [A44]: My revisions to the text have resulted in the figure numbers being changed. However, I have not made any changes to the figure numbers in this document. If my changes seem acceptable to you, I recommend including the revised figure numbers in parentheses in your responses, so that it is easier for the reviewers to check the figures when they refer to the revised manuscript.

Commented [A45]: This comment has been appropriately addressed in the manuscript.

Commented [A46]: I have revised this for consistency.

Commented [A47]: This comment has been appropriately addressed in the manuscript.

Commented [A48]: 1. Please note that this information is not mentioned in the revised manuscript. Please include this at a suitable point in the description of the methods. 2. The comment regarding the higher shift of the first peak as compared with the second peak is not addressed. Please address this in the response and, if applicable, in the revised manuscript.

5. The authors may refer to the studies by Dharmaraj et al., Grushin et al., and Ahmed et al. on the metal complexes and cite them accordingly. In the title for the paper in the reference 13, “Complexation of bis-2-(benzylideneamino)phenol to cobalt(II) and zinc(II), and their spectroscopic studie,” studie should be studies.

Response:

We thank you for suggesting these valuable references. The information provided in these references has improved our understanding of the formation of metal complexes. We have now cited these references at relevant places in the manuscript. The title in reference 13 has also been corrected now.

6. The geometry of the complexes is not mentioned in the text.

Response:

We apologize for not mentioning the geometry of the isomers of the Ru complex. All the complexes were octahedral. We have mentioned this in the revised manuscript.

Commented [A49]: This has been appropriately addressed in the revised manuscript.

Commented [A50]: Changes were made here to improve the clarity and readability of this part. Please check whether the revised part retains the intended meaning.

Commented [A51]: Please note that the geometry was mentioned only in the abstract. I have now included this information in the main text too.